Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Crohn's Disease
Serum and local levels of sRANKL and OPG are increased in CD
January 27th, 2005
Serum and local levels of soluble receptor activator of NF-kappaB ligand and osteoprotegerin are higher in patients with Crohn's disease, gastroenterologists report. According to a study from Belgium, "Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK, and its decoy receptor osteoprotegerin (OPG) are potentially involved in this process as they regulate osteoclastogenesis and are influenced by pro-inflammatory cytokines." N. Franchimont and colleagues, University of Liege, measured "the levels of soluble RANKL (sRANKL), RANK, and OPG...
Source: Women's Health Weekly (2005-01-27)
|
